Top 5 bioproductionconsiderations when scalingyour therapeutic program tothe clinic and beyond

Scaling up new biotherapeutics from development to commercial production is becoming more and more complex with the growing pipeline of advanced biotherapeutics such as cell and gene therapies, RNA therapeutics, and monoclonal antibody variants

Today there are more than 1,100 antibody therapeutics 1 and 4,000 gene, cell, and RNA therapies in the biopharmaceutical pipeline.2 The complexities involved in developing these advanced biotherapeutics are requiring the biopharmaceutical industry to consider everything from how they strengthen their supply chains to how they navigate rapidly changing regulatory requirements.